-
1
-
-
0023717986
-
Staging and prognosis in chronic myelogenous leukemia
-
Sokal JE, Baccarani M, Russo D, et al: Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49-61, 1988.
-
(1988)
Semin Hematol
, vol.25
, pp. 49-61
-
-
Sokal, J.E.1
Baccarani, M.2
Russo, D.3
-
2
-
-
0022350250
-
Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation
-
Sokal JE, Baccarani M, Tura S, et al: Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation. Blood 66:1352-1357, 1985.
-
(1985)
Blood
, vol.66
, pp. 1352-1357
-
-
Sokal, J.E.1
Baccarani, M.2
Tura, S.3
-
3
-
-
0020972981
-
Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
-
Bartram CR, de Klein A, Hagemeijer A, et al: Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-280, 1983.
-
(1983)
Nature
, vol.306
, pp. 277-280
-
-
Bartram, C.R.1
de Klein, A.2
Hagemeijer, A.3
-
4
-
-
0021346853
-
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
-
Groffen J, Stephenson JR, Heisterkamp N, et al: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99, 1984.
-
(1984)
Cell
, vol.36
, pp. 93-99
-
-
Groffen, J.1
Stephenson, J.R.2
Heisterkamp, N.3
-
5
-
-
0025348013
-
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
-
Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990.
-
(1990)
Science
, vol.247
, pp. 1079-1082
-
-
Lugo, T.G.1
Pendergast, A.M.2
Muller, A.J.3
-
6
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006.
-
(2006)
Blood
, vol.108
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
-
7
-
-
34247248807
-
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
-
Kantarjian H, O'Brien S, Talpaz M, et al: Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109:1556-1560, 2007.
-
(2007)
Cancer
, vol.109
, pp. 1556-1560
-
-
Kantarjian, H.1
O'Brien, S.2
Talpaz, M.3
-
8
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996.
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
-
9
-
-
15444350807
-
Selective inhibition of cell proliferation and BCR, ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
-
Beran M, Can X, Estrov Z, et al: Selective inhibition of cell proliferation and BCR, ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148), Clin Cancer Res 4:1661-1672, 1998.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1661-1672
-
-
Beran, M.1
Can, X.2
Estrov, Z.3
-
10
-
-
0031409736
-
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
-
Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394, 1997.
-
(1997)
Blood Cells Mol Dis
, vol.23
, pp. 380-394
-
-
Gambacorti-Passerini, C.1
le Coutre, P.2
Mologni, L.3
-
11
-
-
10744233716
-
Imatinib compared With interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared With interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
-
12
-
-
33748791111
-
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study (abstract 6506)
-
338s
-
Druker B, Guilhot, F, O'Brien S, et al: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study (abstract 6506). J Clin Oncol 24(18S):338s, 2006.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
-
-
Druker, B.1
Guilhot, F.2
O'Brien, S.3
-
13
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006.
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
-
14
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001.
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
-
15
-
-
4344672552
-
Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance
-
Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 18:1321-1331, 2004.
-
(2004)
Leukemia
, vol.18
, pp. 1321-1331
-
-
Hochhaus, A.1
La Rosee, P.2
-
16
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
-
17
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001.
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
-
18
-
-
19244366937
-
Minimal residual disease in chronic myeloid leukemia
-
Lowenberg B: Minimal residual disease in chronic myeloid leukemia. N Engl J Med 349:1399-1401, 2003.
-
(2003)
N Engl J Med
, vol.349
, pp. 1399-1401
-
-
Lowenberg, B.1
-
19
-
-
0038375012
-
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
-
Corbin AS, La Rosee P, Stoffregen EP, et al: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614, 2003.
-
(2003)
Blood
, vol.101
, pp. 4611-4614
-
-
Corbin, A.S.1
La Rosee, P.2
Stoffregen, E.P.3
-
20
-
-
0037315281
-
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
-
Gambacorti-Passerini CB, Gunby RH, Piazza R, et al: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4:75-85, 2003.
-
(2003)
Lancet Oncol
, vol.4
, pp. 75-85
-
-
Gambacorti-Passerini, C.B.1
Gunby, R.H.2
Piazza, R.3
-
21
-
-
65449137398
-
Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy (abstract 1938)
-
Quintas-Cardama A, Gibbons DL, Kantarjian H, et al: Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy (abstract 1938). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Quintas-Cardama, A.1
Gibbons, D.L.2
Kantarjian, H.3
-
22
-
-
0034665713
-
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
-
Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942, 2000.
-
(2000)
Science
, vol.289
, pp. 1938-1942
-
-
Schindler, T.1
Bornmann, W.2
Pellicena, P.3
-
23
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare T, Waiters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505, 2005.
-
(2005)
Cancer Res
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Waiters, D.K.2
Stoffregen, E.P.3
-
24
-
-
15944404601
-
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
-
Deininger M, Buchdunger E, Druker B J: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653, 2005.
-
(2005)
Blood
, vol.105
, pp. 2640-2653
-
-
Deininger, M.1
Buchdunger, E.2
Druker, B.J.3
-
25
-
-
23344440655
-
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
-
Carter TA, Wodicka LM, Shah NP, et al: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102:11011-11016, 2005.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 11011-11016
-
-
Carter, T.A.1
Wodicka, L.M.2
Shah, N.P.3
-
26
-
-
0036682301
-
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
-
Nagar B, Bornmann WG, Pellicena P, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 4236-4243
-
-
Nagar, B.1
Bornmann, W.G.2
Pellicena, P.3
-
27
-
-
0344626925
-
A myristoyl/phosphotyrosine switch regulates c-Abl
-
Hantschel O, Nagar B, Guettler S, et al: A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112:845-857, 2003.
-
(2003)
Cell
, vol.112
, pp. 845-857
-
-
Hantschel, O.1
Nagar, B.2
Guettler, S.3
-
28
-
-
0037459344
-
Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL
-
Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831-843, 2003.
-
(2003)
Cell
, vol.112
, pp. 831-843
-
-
Azam, M.1
Latek, R.R.2
Daley, G.Q.3
-
29
-
-
0037438640
-
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
-
Donato NJ, Wu JY, Stapley J, et al: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698, 2003.
-
(2003)
Blood
, vol.101
, pp. 690-698
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
-
30
-
-
13844251975
-
Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E, Manley PW, Breitenstein W, et al: Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141, 2005.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
31
-
-
33847379510
-
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
-
Weisberg E, Catley L, Wright RD, et al: Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109:2112-2120, 2007.
-
(2007)
Blood
, vol.109
, pp. 2112-2120
-
-
Weisberg, E.1
Catley, L.2
Wright, R.D.3
-
32
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006.
-
(2006)
N Engl J Med
, vol.354
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
-
33
-
-
43549116467
-
Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance (abstract 735)
-
Kantarjian H, Hochhaus, A, Cortes, J, et al: Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance (abstract 735). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Kantarjian, H.1
Hochhaus, A.2
Cortes, J.3
-
34
-
-
62649160345
-
Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance (abstract 471)
-
le Coutre P, Giles FJ, Apperley J, et al: Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance (abstract 471). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
le Coutre, P.1
Giles, F.J.2
Apperley, J.3
-
35
-
-
43549112174
-
Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CME-BC) who are resistant or intolerant to imatinib (abstract 1025)
-
Giles F, Larson RA, Kantarjian K, et al: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CME-BC) who are resistant or intolerant to imatinib (abstract 1025). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Giles, F.1
Larson, R.A.2
Kantarjian, K.3
-
36
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-me-thylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
Lombardo LJ, Lee FY, Chen P, et al: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-me-thylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661, 2004.
-
(2004)
J Med Chem
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
37
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004.
-
(2004)
Science
, vol.305
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
-
38
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006.
-
(2006)
N Engl J Med
, vol.354
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
-
39
-
-
29144492198
-
BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo (abstract 675)
-
Lee F, Lombardo, L, Camuso, A, et al: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo (abstract 675). Proc Am Assoc Cancer Res 46:159, 2005.
-
(2005)
Proc Am Assoc Cancer Res
, vol.46
, pp. 159
-
-
Lee, F.1
Lombardo, L.2
Camuso, A.3
-
40
-
-
49249109701
-
Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) (abstract 734)
-
Stone R, Kantarjian H, Baccarani M, et al: Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) (abstract 734). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Stone, R.1
Kantarjian, H.2
Baccarani, M.3
-
41
-
-
49249109701
-
Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) (abstract 470)
-
Guilhot F, Apperley JF, Kim D, et al: Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) (abstract 470). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Guilhot, F.1
Apperley, J.F.2
Kim, D.3
-
42
-
-
58649117545
-
Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program (abstract 472)
-
Gambacorti C, Cortes J, Kim D, et al: Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program (abstract 472). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Gambacorti, C.1
Cortes, J.2
Kim, D.3
-
43
-
-
62649172099
-
Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) (abstract 1035)
-
Jabbour E, Kantarjian H, Atallah E, et al: Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) (abstract 1035). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Jabbour, E.1
Kantarjian, H.2
Atallah, E.3
-
44
-
-
58649121459
-
Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) (abstract 736)
-
Kantarjian H, Rousselot P, Pasquini R, et al: Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) (abstract 736). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Kantarjian, H.1
Rousselot, P.2
Pasquini, R.3
-
45
-
-
33845806858
-
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
-
Puttini M, Coluccia AM, Boschelli F, et al: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66:11314-11322, 2006.
-
(2006)
Cancer Res
, vol.66
, pp. 11314-11322
-
-
Puttini, M.1
Coluccia, A.M.2
Boschelli, F.3
-
46
-
-
65449178270
-
A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib (abstract 168)
-
Cortes J, Kantarjian, H, Baccarani, M, et al: A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib (abstract 168). Blood 108, 2006.
-
(2006)
Blood
, vol.108
-
-
Cortes, J.1
Kantarjian, H.2
Baccarani, M.3
-
47
-
-
34548523623
-
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
-
Quintas-Cardama A, Kantarjian H, O'Brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3908-3914
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
O'Brien, S.3
-
48
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study
-
Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539, 2002.
-
(2002)
Blood
, vol.99
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
-
49
-
-
65449186066
-
Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) (abstract 733)
-
Cores J, Bruemmendorf, T, Kantarjian H, et al: Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) (abstract 733). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Cores, J.1
Bruemmendorf, T.2
Kantarjian, H.3
-
50
-
-
47649093491
-
Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL (abstract 473)
-
Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL (abstract 473). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Gambacorti-Passerini, C.1
Kantarjian, H.2
Bruemmendorf, T.3
-
51
-
-
33846018356
-
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
-
Yokota A, Kimura S, Masuda S, et al: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109:306-314, 2007.
-
(2007)
Blood
, vol.109
, pp. 306-314
-
-
Yokota, A.1
Kimura, S.2
Masuda, S.3
-
52
-
-
45749104554
-
A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors (abstract 469)
-
Kantarjian H, Cortes, J, le Coutre, P, et al: A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors (abstract 469). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Kantarjian, H.1
Cortes, J.2
le Coutre, P.3
-
53
-
-
55949130519
-
IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 25)
-
Hochhaus A, Druker B J, Larson R, et al: IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 25). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Hochhaus, A.1
Druker, B.J.2
Larson, R.3
-
54
-
-
35248867857
-
Tyrosine kinase inhibitors for chronic myelogenous leukemia (letter)
-
incl author reply
-
Quintas-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia (letter). N Engl J Med 357:1557-1558 (incl author reply), 2007.
-
(2007)
N Engl J Med
, vol.357
, pp. 1557-1558
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Cortes, J.3
-
55
-
-
43549116467
-
Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib (abstract 1036)
-
Kantarjian H, Quintas-Cardama, A, O'Brien, S, et al: Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib (abstract 1036). Blood 110, 2007.
-
(2007)
Blood
, vol.110
-
-
Kantarjian, H.1
Quintas-Cardama, A.2
O'Brien, S.3
|